Read this company snapshot
Daily valuation snapshot
Entera Bio Ltd. Ordinary Shares: source evidence dated 2026-10-09.
- Daily close (USD)
- $2.66
- Market capitalization (USD)
- $131,112,019.78
- Price / earnings (TTM)
- Not reported
- Price / book
- 18.04
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ENTX in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research ENTX in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Entera Bio Ltd., a clinical stage company, focuses on developing oral peptide or protein replacement therapies for unmet medical needs. The company leverages its N-Tab platform that is designed to simultaneously stabilize the peptide in the gastrointestinal tract and promote its absorption into the bloodstream. It also develops EB613, an oral PTH (1-34), that has completed Phase 2 clinical trial for the treatment of post-menopausal women with low bone mineral density and high-risk osteoporosis; and has completed Phase 1 clinical trial to treat stress fractures. In addition, the company is developing EB612, a tablet peptide replacement therapy for hypoparathyroidism. Further, it develops oral oxyntomodulin (OXM), a dual targeted GLP1/glucagon peptide, in tablet form for the treatment of obesity and metabolic disorders; and GLP-2 peptide tablet as an injection-free alternative for patients suffering from rare malabsorption conditions, such as short bowel syndrome. The company has research collaboration agreement with OPKO Biologics, Inc. Entera Bio Ltd. was incorporated in 2009 and is headquartered in Jerusalem, Israel.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing ENTX with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $2.66 |
| Market capitalization (USD) | $131,112,019.78 |
| Price / earnings (TTM) | Not reported |
| Price / book | 18.04 |
No matching rows. Clear the filter to see all records.
Read ENTX's valuation metrics
Company size
Entera Bio Ltd. Ordinary Shares's recorded market capitalization is $131,112,019.78. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
ENTX's recorded price-to-book ratio is 18.04. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Entera Bio Ltd. Ordinary Shares with Aurora
Use the snapshot above to ask a specific question about ENTX. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow ENTX's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.